US 12,465,660 B2
Compositions and methods for cancer imaging and radiotherapy
Cédric Malicet, Marseilles (FR); Pascaline Lecorche, Marseilles (FR); Jonathan Nowak, Marseilles (FR); Marion David, Marseilles (FR); Jamal Temsamani, Nimes (FR); and Michel Khrestchatisky, Marseilles (FR)
Assigned to VECT-HORUS, Marseilles (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and UNIVERSITE D'AIX MARSEILLE, Marseilles (FR)
Filed by VECT-HORUS, Marseilles (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and UNIVERSITE D'AIX-MARSEILLE, Marseilles (FR)
Filed on Jul. 28, 2023, as Appl. No. 18/360,859.
Application 18/360,859 is a continuation of application No. 16/479,234, granted, now 11,712,486, previously published as PCT/EP2018/052234, filed on Jan. 30, 2018.
Claims priority of application No. 17305098 (EP), filed on Jan. 30, 2017.
Prior Publication US 2024/0100204 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/08 (2006.01); A61K 51/04 (2006.01); C07K 7/06 (2006.01); G01N 33/574 (2006.01); G01N 33/60 (2006.01); G01N 33/92 (2006.01)
CPC A61K 51/088 (2013.01) [A61K 51/048 (2013.01); C07K 7/06 (2013.01); G01N 33/57438 (2013.01); G01N 33/60 (2013.01); G01N 33/92 (2013.01); A61K 2121/00 (2013.01); A61K 2123/00 (2013.01)] 8 Claims
 
1. A conjugated compound of formula M-C-P,
wherein:
M represents a pharmaceutically acceptable radionuclide,
C represents a chelating cage forming a chelate with M, wherein said chelating cage is selected from:
(i) DOTA and a functional derivative of DOTA,
(ii) NODAGA and a functional derivative of NODAGA,
(iii) NOTA and a functional derivative of NOTA,
(iv) DOTA-GA and a functional derivative of DOTA-GA,
wherein the functional derivative of DOTA, functional derivative of NODAGA, functional derivative of NOTA, or functional derivative of DOTA-GA is a compound in which one or more hydroxyl group is replaced by an amine group, and
P represents a peptide or pseudo-peptide comprising an amino acid sequence selected from any one of SEQ ID NO: 1 to SEQ ID NO: 9, said peptide or pseudo-peptide having at most 30 amino acid residues and binding Low-Density Lipoprotein Receptor (LDLR).